Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | USP14 | P54578 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21688016 | 0.97 | KDM4E (0.34) | RARGUSP14TDP2ALDH1A1LMNA | |
| SCHEMBL21687487 | 0.91 | LMNA (0.35) | TDP2ALDH1A1LMNAHPGDMAPK1 | |
| SCHEMBL21687990 | 0.89 | ALDH1A1 (0.34) | RARGUSP14TDP2ALDH1A1LMNA | |
| SCHEMBL21687689 | 0.89 | KDM4E (0.34) | TDP2ALDH1A1LMNAHPGDMAPK1 | |
| SCHEMBL21688070 | 0.88 | PTGER4 (0.33) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21688077 | 0.88 | KDM4E (0.41) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687993 | 0.87 | SMN1; SMN2 (0.34) | RARGTDP2ALDH1A1LMNAHPGD | |
| SCHEMBL21687873 | 0.87 | CYP1A2 (0.32) | ALDH1A1LMNAMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL21687531 | 0.86 | KDM4E (0.34) | RARGALDH1A1LMNAHPGDMAPK1 | |
| SCHEMBL21688067 | 0.86 | PTGER4 (0.33) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-12-14 | — | — | US | disclosed |
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | CRY1, CCNL2, CCNE2 | RARG 1498/4885USP14 3552/4885TDP2 4123/4885 |
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | CRY1, CCNL2, CCNE2 | RARG 1498/4885USP14 3552/4885TDP2 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.